Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$23.23M$23.23M+16.4% vs Q3 2020 Net Income-$52.41M-$52.41MN/M vs Q3 2020 EPS Diluted-$0.51-$0.51N/M vs Q3 2020 Operating Income-$51,708,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$54,697,000N/M Margins · derivedOperating margin-222.6%+69.8 pt vs Q3 2020
Net margin-225.6%+66.0 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 3, 2021 · 34 d after period end